Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis.

Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis.

J Dermatolog Treat. 2018 Apr 23;:1-10

Authors: Dias-Polak D, Bergman R, Avitan-Hersh E

Abstract
Patients with severe atopic dermatitis (AD) may require potent immunosuppressive therapy to control their disease. Mycophenolate mofetil (MMF) has been suggested as a safe and effective drug in these cases. We have used oral MMF 2-3gr/day in adult patients with severe recalcitrant AD who failed other major systemic drugs, or where other drugs, including cyclosporine, methotrexate and azathioprine, were contraindicated. Of 9 consecutive adult patients, 4 (44%) responded completely, 2 (22%) had partial response and 3 (33%) did not respond at all. The MMF therapy was continued for 5-36 months (average 21 months) without major side effects. Our results demonstrate that oral MMF may be an effective drug in AD. Due to its good safety profile, it may be recommended as a first line systemic therapy, or successive to cyclosporine in the long term.

PMID: 29683760 [PubMed - as supplied by publisher]

https://ift.tt/2Jo75Wr